Phospho-CD22 (Tyr807) Antibody

What is CD22 and what role does Tyr807 phosphorylation play in B cell signaling?

CD22 (also known as Siglec-2 or BL-CAM) is a receptor predominantly restricted to B cells that functions as a key regulator of B cell receptor (BCR) signaling. CD22 contains immunoreceptor tyrosine-based inhibition motifs (ITIMs) in its cytoplasmic tail that, when phosphorylated, recruit inhibitory molecules.

Specifically, Tyr807 phosphorylation on CD22 is involved in the recruitment of the adaptor protein Grb2. Unlike the two distal ITIMs that recruit SHP-1 phosphatase, the Tyr807 residue (Y828 in humans) forms a complex with Grb2 and Shc that can activate a MAP kinase pathway regulating cell survival and proliferation . This phosphorylation event represents an important regulatory mechanism distinct from the classic ITIM phosphorylation, suggesting CD22 has more nuanced functions beyond simple inhibition of B cell activation.

How does CD22 Tyr807 phosphorylation differ from other phosphorylation sites on CD22?

CD22 contains multiple tyrosine residues in its cytoplasmic domain that serve different functions when phosphorylated:

Unlike the ITIM sites (Tyr822 and Tyr842) that primarily mediate inhibitory functions, Tyr807 phosphorylation has been associated with both signaling attenuation and potential positive regulatory effects. Research indicates that BCR ligation induces phosphorylation of both the ITIMs and the Grb2 recruitment motif, while CD40 ligation only induces phosphorylation of the ITIM domains . This selective phosphorylation pattern suggests context-specific roles for CD22 in different signaling pathways.

What are the recommended experimental approaches for detecting CD22 Tyr807 phosphorylation in primary B cells?

Several complementary approaches can be used to detect CD22 Tyr807 phosphorylation in primary B cells:

When working with primary B cells, researchers should be aware that there can be high basal phosphorylation of certain CD22 tyrosine residues (particularly Tyr842 and Tyr822), which may complicate interpretation of stimulation experiments .

How can I optimize Western blotting conditions for detecting Phospho-CD22 (Tyr807)?

For optimal Western blot detection of Phospho-CD22 (Tyr807), consider the following methodological recommendations:

• Antibody selection: Use highly specific antibodies validated for Western blotting. Based on the search results, recommended dilutions for Western blotting range from 1:500 to 1:2000 .

• Sample preparation:

  • Quick lysis is essential to preserve phosphorylation status

  • Include phosphatase inhibitors in all buffers

  • For BCR stimulation experiments, stimulate cells with anti-IgM F(ab')₂ (positive control) alongside experimental conditions

  • Include both stimulated and unstimulated samples as controls

• Controls:

  • Use a non-phospho-specific CD22 antibody in parallel to normalize for total CD22 expression

  • Consider using CD22-deficient cell lines as negative controls

  • Include positive controls such as BCR-stimulated B cells, which strongly induce CD22 tyrosine phosphorylation

• Time-course analysis: Phosphorylation of Tyr807 may peak at different times than other sites. In Daudi cells, signals appear strongest after 5 minutes of stimulation , but timing may vary in primary cells.

How does Tyr807 phosphorylation on CD22 coordinate with other inhibitory receptors to regulate B cell signaling?

CD22 Tyr807 phosphorylation operates within a complex network of inhibitory receptors that collectively fine-tune B cell responses:

• Coordination with CD32B: Research demonstrates that engagement of CD22 with epratuzumab leads to phosphorylation of not only CD22 Tyr807 but also Tyr292 on CD32B (the low-affinity inhibitory Fc receptor) . This dual phosphorylation suggests a coordinated inhibitory mechanism where CD22 engagement can trigger multiple inhibitory pathways simultaneously.

• Grb2-mediated effects: The phosphorylated Tyr807 site recruits Grb2, which has been previously implicated in the negative regulation of Ca²⁺ in B cells through its localization by the adaptor protein Dok-3 to the plasma membrane and subsequent inhibition of Btk . CD22, as a substrate for Lyn, may help facilitate this process.

• Regulation of calcium signaling: Although independent of the ITIM-SHP-1 pathway, the Tyr807-Grb2 interaction appears to affect calcium regulation. Chen et al. found that CD22 can associate with plasma membrane calcium ATPase (PMCA) to enhance calcium efflux after BCR ligation; this association requires tyrosine phosphorylation of CD22 at the non-ITIM Y828 site (equivalent to Y807) that associates with Grb2 .

This coordinated activity suggests that CD22 functions as part of an integrated inhibitory network rather than as an isolated inhibitory receptor.

What are the functional consequences of disrupting CD22 Tyr807 phosphorylation in B cell signaling and autoimmunity models?

Disruption of CD22 Tyr807 phosphorylation has several significant functional consequences:

Targeted mutagenesis of Tyr807 specifically (rather than complete CD22 knockout) would be necessary to fully elucidate its unique role in these processes.

How can I distinguish between specific Tyr807 phosphorylation and background signal in my experiments?

Distinguishing specific Tyr807 phosphorylation from background requires rigorous controls and validation:

• Antibody validation: Confirm the specificity of your phospho-specific antibody. The search results indicate that some commercial antibodies are produced against synthesized peptides derived from human BL-CAM/CD22 around the phosphorylation site of Tyr807 . These antibodies are often purified using affinity-chromatography with epitope-specific phosphopeptides, and non-phospho specific antibodies are removed by chromatography using non-phosphopeptides .

• Essential controls:

  • Negative control: Use CD22-deficient cells or siRNA knockdown

  • Dephosphorylation control: Treat samples with phosphatase to eliminate phospho-specific signal

  • Competing peptide: Pre-incubation of antibody with the phospho-peptide used as immunogen should abolish specific signal

  • Multiple detection methods: Confirm results using both immunoprecipitation and flow cytometry approaches, as demonstrated in studies of epratuzumab effects

• Basal phosphorylation assessment: Be aware that primary B cells may have high constitutive phosphorylation of certain CD22 tyrosine residues. For instance, experiments with tonsil-derived purified B cells revealed high basal phosphorylation of Tyr842 and Tyr822, while Tyr807 showed lower basal phosphorylation and was more responsive to stimulation .

What are the common technical challenges in detecting CD22 Tyr807 phosphorylation and how can they be overcome?

Researchers face several technical challenges when analyzing CD22 Tyr807 phosphorylation:

• High basal phosphorylation in primary cells:

  • Challenge: Primary B cells often show high constitutive phosphorylation of CD22 tyrosine residues (particularly Tyr842 and Tyr822) .

  • Solution: Focus on fold-changes rather than absolute values; use careful normalization to total CD22; consider serum-starving cells briefly to reduce basal signaling.

• Temporal dynamics:

  • Challenge: Phosphorylation events are often transient and occur in specific time windows.

  • Solution: Perform detailed time-course experiments. Research shows that in Daudi cells, BCR-induced phosphorylation of all three tyrosine residues (Tyr822, Tyr842, and Tyr807) is strongest after 5 minutes, while epratuzumab-induced phosphorylation of Tyr807 in primary cells may occur at later time points .

• Antibody specificity:

  • Challenge: Ensuring antibodies specifically detect phosphorylated Tyr807 without cross-reactivity.

  • Solution: Use antibodies that have been validated by affinity purification with phospho-specific peptides and removal of non-phospho reactive antibodies ; confirm specificity with peptide competition assays.

• Cell heterogeneity:

  • Challenge: Different B cell subsets may show variable CD22 phosphorylation patterns.

  • Solution: Use flow cytometry to analyze phosphorylation events in specific B cell subpopulations (e.g., CD27+ memory vs. CD27- naïve B cells) .

How can Phospho-CD22 (Tyr807) antibodies be utilized to study B cell dysregulation in autoimmune diseases?

Phospho-CD22 (Tyr807) antibodies offer valuable tools for investigating B cell dysregulation in autoimmune contexts:

• Baseline phosphorylation assessment: Compare basal Tyr807 phosphorylation levels in B cells from healthy donors versus patients with autoimmune conditions. Altered baseline phosphorylation could indicate intrinsic differences in B cell inhibitory threshold.

• Response to BCR stimulation: Analyze the kinetics and magnitude of Tyr807 phosphorylation following BCR stimulation in patient-derived B cells. Studies have shown that CD22 regulates BCR signaling, and CD22-deficient B cells exhibit elevated responses such as increased intracellular calcium mobilization .

• Therapeutic response monitoring: Phospho-CD22 (Tyr807) antibodies can be used to evaluate B cell responses to therapeutics that target B cells. For example, epratuzumab (anti-CD22 antibody) has been shown to induce phosphorylation of Tyr807 on CD22 and enhance its co-localization with signaling molecules , suggesting a mechanism by which this therapeutic antibody modulates B cell function.

• Multi-parameter analysis: Combine phospho-CD22 (Tyr807) detection with analysis of other signaling molecules (e.g., SHP-1, CD32B phosphorylation) to build a comprehensive picture of B cell signaling networks in autoimmunity. Flow cytometry approaches allow for simultaneous analysis of multiple parameters within specific B cell subsets .

What experimental designs are most effective for studying the interplay between CD22 Tyr807 phosphorylation and TLR signaling in B cells?

To effectively investigate the relationship between CD22 Tyr807 phosphorylation and TLR signaling, consider these experimental approaches:

• Sequential stimulation experiments:

  • Design: Pre-treat B cells with TLR ligands (e.g., LPS, CpG) before BCR stimulation and measure Tyr807 phosphorylation, or vice versa.

  • Rationale: CD22-deficient B cells show hyperresponsiveness to TLR agonists , but the specific role of Tyr807 phosphorylation remains unclear.

  • Analysis: Compare phosphorylation patterns, calcium flux, and downstream signaling pathways activation.

• Co-localization studies:

  • Design: Use confocal microscopy to examine the physical relationship between CD22 and TLR-containing endosomes after various stimuli.

  • Rationale: CD22 is an endocytic receptor that recycles between the cell surface and endosomes where endosomal TLRs reside . Changes in CD22 concentration in endosomes may affect TLR signaling.

  • Approach: Conduct immunofluorescence microscopy with dual labeling for CD22 and TLRs, including phospho-specific detection of Tyr807.

• Site-directed mutagenesis:

  • Design: Create B cell lines expressing CD22 with specific mutations at Tyr807 (Y807F to prevent phosphorylation) and assess responses to TLR ligands.

  • Readouts: Measure cytokine production, proliferation, and activation markers after TLR stimulation.

• SOCS protein analysis:

  • Design: Monitor expression of SOCS1 and SOCS3 (suppressors of cytokine signaling) after TLR stimulation in cells with normal versus disrupted CD22 Tyr807 phosphorylation.

  • Rationale: CD22 normally may function during TLR signaling to activate SOCS proteins that blunt responses to TLR ligands .

These experimental designs would help elucidate the specific contribution of CD22 Tyr807 phosphorylation to the regulation of TLR signaling in B cells, potentially revealing new insights into how these signaling pathways interact in both normal immune responses and autoimmune conditions.